AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

In the ever-evolving world of wellness and self-care, finding the right supplement can sometimes feel like searching for a ...

A holistic approach that considers both physical and psychological aspects can help achieve and maintain a healthy weight ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Life Time Group Holdings is best-known for its fitness clubs, but executives see plenty of room to grow in the field of ...

Our weight tends to fluctuate as we get older because of slowing metabolism and other factors. But there are weight ...